Budget Amount *help |
¥40,430,000 (Direct Cost: ¥31,100,000、Indirect Cost: ¥9,330,000)
Fiscal Year 2017: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
Fiscal Year 2016: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
Fiscal Year 2015: ¥19,240,000 (Direct Cost: ¥14,800,000、Indirect Cost: ¥4,440,000)
|
Outline of Final Research Achievements |
For the success of the cancer immune therapy, activation of antigen-specific cytotoxic T cell (CTL) is quite important. DNA vaccine is principally useful technology to induce this CTL activity. Meanwhile, the intra-tumor region is considered to be an immune-suppressive environment. Thus, for the effective function of the cancer vaccine, the normalization/ neutralization of the immune-suppressive machinery is essential in parallel. Currently, we have developed a lipid nanoparticle composed of intracellular environment-responsive material (ss-cleavable and pH-activated lipid-like material: ssPalm) as a technology to overcome the biomembranes barrier, and spontaneous collapse. In this project, we developed a delivery system of Genes, and small compounds using ssPalm as a fundamental platform, and applied them for the immune-engineering for cancer therapy.
|